Topical Minocycline for CARP

This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP). Participants will apply AMZEEQ® to one side of the body and a topical emollient to the other for 5 weeks, followed by an optional extension period. The study aims to assess whether topical minocycline is a well-tolerated and effective alternative to oral antibiotics.

NCT Number	NCT07462702
Lead Sponsor	Medical University of South Carolina Collaborators: Journey Medical Corporation
Conditions	Confluent and Reticulated Papillomatosis (CARP)
Enrollment	35 participants
Start Date	2026-09-15
Primary Completion	2027-08 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-21